HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Tarek M. Aziz Jonathan Forty Colin J. Hilton Asif Hasan John H. Dark Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aziz, T. M. Articles by Dark, J. H. Search for Related Content PubMed PubMed Citation Articles by Aziz, T. M. Articles by Dark, J. H. Related Collections Pleura

Ann Thorac Surg 2003;75:990-995
© 2003 The Society of Thoracic Surgeons

---

Original article: general thoracic

Perfadex for clinical lung procurement: is it an advance?

^a Transplant Unit, Freeman Hospital, Newcastle upon-Tyne, United Kingdom

Accepted for publication September 16, 2002.

^* Address reprint requests to Dr Aziz, Division of Cardiothoracic Surgery, Morriston Hospital, Morriston, Swansea, West Glamorgan, Wales SW6 6NL2, United Kingdom
e-mail: tarekaziz55{at}hotmail.com

BACKGROUND: Extensive laboratory experience suggested that low potassium dextran lung preservation solution (Perfadex; Medisan, Uppsala, Sweden) is superior to Euro-Collins (EC; Frusen, Hamburg, Germany), the clinical standard. The purpose of this study was to evaluate Perfadex in clinical lung transplantation.

METHODS: A retrospective analysis of the outcome of 69 consecutive lung allografts retrieved and used for transplantation was made. Donor lungs were flushed with EC in 37 patients and Perfadex in 32 patients. The evaluation measurements were quantitative chest roentgenogram score (grade 0 to 4), graft oxygenation, duration of mechanical ventilation, length of intensive care treatment, and survival.

RESULTS: The mean chest roentgenogram score was 1.55 and 1.81 for the EC group compared with 1.18 and 2.09 for the Perfadex group at 1 and 48 hours, respectively (p = 0.1 and 0.8, respectively). Arterial alveolar oxygen tension ratio was similar at 12 and 24 hours (0.61 vs 0.67; p = 0.8; and 0.64 vs 0.53; p = 0.3, respectively). The mean ventilation time was 71.2 ± 32.3 hours versus 81.9 ± 43.6 hours for the EC and Perfadex groups, respectively (p = 0.4). The mean ITU stay was 3.1 ± 2.6 days for the EC group compared with 4.1 ± 3.9 days for the Perfadex group (p = 0.4). Death caused by primary organ failure was 5.1% for the EC group compared with 3.1% for the Perfadex group (p = 0.8).

CONCLUSIONS: There was no difference between Perfadex and EC in clinical lung preservation. This may reflect the difference between controlled laboratory environment and the real world of brain death lung injury. Further studies are required to investigate the impact of Perfadex in the long-term outcome of lung transplantation.

This article has been cited by other articles:

				G. Ailawadi, C. L. Lau, P. W. Smith, B. R. Swenson, S. A. Hennessy, C. J. Kuhn, L. M. Fedoruk, B. D. Kozower, I. L. Kron, and D. R. Jones Does reperfusion injury still cause significant mortality after lung transplantation? J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 688 - 694. [Abstract] [Full Text] [PDF]

				P. Ferraro, J. Martin, J. Dery, J. Prenovault, L. Samson, M. Coutu, L.-Q. Chen, C. Poirier, N. Noiseux, A. Duranceau, et al. Late Retrograde Perfusion of Donor Lungs Does Not Decrease the Severity of Primary Graft Dysfunction Ann. Thorac. Surg., October 1, 2008; 86(4): 1123 - 1129. [Abstract] [Full Text] [PDF]

				J. S. Ganesh, C. A. Rogers, N. R. Banner, R. S. Bonser, and Steering Group of the UK Cardiothoracic Transplant Does the method of lung preservation influence outcome after transplantation? An analysis of 681 consecutive procedures. J. Thorac. Cardiovasc. Surg., November 1, 2007; 134(5): 1313 - 1321. [Abstract] [Full Text] [PDF]

				T. Oto, A. P. Griffiths, F. Rosenfeldt, B. J. Levvey, T. J. Williams, and G. I. Snell Early Outcomes Comparing Perfadex, Euro-Collins, and Papworth Solutions in Lung Transplantation Ann. Thorac. Surg., November 1, 2006; 82(5): 1842 - 1848. [Abstract] [Full Text] [PDF]

				H. B. Bittner, M. Richter, T. Kuntze, A. Rahmel, P. Dahlberg, M. Hertz, and F. W. Mohr Aprotinin decreases reperfusion injury and allograft dysfunction in clinical lung transplantation Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 210 - 215. [Abstract] [Full Text] [PDF]

				D. Lardinois, M. Banysch, S. Korom, S. Hillinger, V. Rousson, A. Boehler, R. Speich, and W. Weder Extended donor lungs: eleven years experience in a consecutive series Eur. J. Cardiothorac. Surg., May 1, 2005; 27(5): 762 - 767. [Abstract] [Full Text] [PDF]

				I. Matsumoto, M. Oda, Y. Tsunezuka, M. Tamura, K. Kawakami, and G. Watanabe Experimental study of extracorporeal lung resection in dogs: Ex situ sleeve resection and autotransplantation of the pulmonary lobe after extended pneumonectomy for central lung cancer J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1343 - 1349. [Abstract] [Full Text] [PDF]

				S. M. Levine and L. F. Angel Primary Graft Failure: Who Is at Risk? Chest, October 1, 2003; 124(4): 1190 - 1192. [Full Text] [PDF]